ClearPoint Neuro (CLPT): Director received 265 shares at $21.79

Rhea-AI Filing Summary

R. John Fletcher, a director of ClearPoint Neuro, Inc. (CLPT), received 265 shares of the issuer's common stock on 10/01/2025 as payment of director fees under the company's Sixth Amended and Restated 2013 Incentive Compensation Plan and Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price on 9/30/2025 of $21.79 per share. After this transaction Fletcher beneficially owned 116,240 shares, held directly. The Form 4 was signed by power of attorney and filed on 10/02/2025.

Insider Trade Summary

Grant/Award: 265 shares

Grant/Award 1 txn

Insider FLETCHER R JOHN

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	265	$21.79	$6K

Holdings After Transaction: Common Stock — 116,240 shares (Direct)

Footnotes (1)

1. F1. These shares were issued pursuant to the issuer's Sixth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at September 30, 2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What transaction did ClearPoint Neuro director R. John Fletcher report on Form 4 (CLPT)?

The Form 4 reports that R. John Fletcher acquired 265 shares of ClearPoint Neuro common stock on 10/01/2025.

At what price were the shares issued to the director in the CLPT Form 4?

The shares were issued at the closing price on 9/30/2025 of $21.79 per share.

How many ClearPoint Neuro shares does R. John Fletcher beneficially own after the reported transaction?

After the transaction, Fletcher beneficially owned 116,240 shares, held directly.

Why were the 265 shares issued to the reporting person?

The 265 shares were issued in payment of fees owed under the issuer's Non-Employee Director Compensation Plan, pursuant to the Sixth Amended and Restated 2013 Incentive Compensation Plan.

When was the Form 4 filed for this transaction?

The Form 4 shows a filing date of 10/02/2025, with the transaction dated 10/01/2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/02/2025 - 07:09 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

FLETCHER R JOHN

(Last) (First) (Middle)

C/O CLEARPOINT NEURO, INC.

120 S. SIERRA AVE., SUITE 100

(Street)

SOLANA BEACH CA 92075

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ClearPoint Neuro, Inc. [ CLPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/01/2025		A		265	A	$21.79(1)	116,240	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares were issued pursuant to the issuer's Sixth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at September 30, 2025.

	/s/ Danilo D'Alessandro, by Power of Attorney for R. John Fletcher	10/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.